DigestRedComo funciona
Red
/
Empresas
Zy
No verificado

Zymeworks Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasMedicina Salud BienestarVenta al público/Minorista

36 Comunicados de prensa

Ver todos los comunicados de prensa
02/03/2026
Biotecnología
Finanzas
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
27/01/2026
Biotecnología
Zymeworks Announces Participation in Upcoming Investor Conferences
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
12/01/2026
Biotecnología
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
11/01/2026
Biotecnología
Medicina Salud Bienestar
Venta al público/Minorista
Anuncios breves
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
06/01/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnología
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnología
Anuncios breves
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnología
Medicina Salud Bienestar
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnología
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0
13/10/2025
Biotecnología
Medicina Salud Bienestar
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Fuente
Zymeworks Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0